• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Show Search
Home
EN / FR
  • LinkedIn
  • Twitter
Celyad Oncology

Celyad Oncology

  • About Us
    • Overview
    • Management Team
    • Board Of Directors
    • Scientific Advisory Board
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • TIM
      • shRNA
    • Manufacturing
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Contact Us
    • Careers

Cardio3 BioSciences Receives Authorization to Begin World’s First Phase III Clinical Trial in Regenerative Medicine for Heart Failure in Spain

September 30, 2013 By Celyad

  • To date, six countries have granted authorization for Cardio3 BioSciences’ Phase III (CHART-1) 
  • CHART-1 trial represents the world’s first Phase III trial for a preprogrammed cellular therapy targeting heart failure

Mont-Saint-Guibert, Belgium – The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, today announces it has received authorization from the Spanish Agency for Medicines and Health Products (AEMPS) to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C-Cure® in Spain. 

Spain is the sixth country to have authorized this unique study after the United Kingdom, Belgium, Israel, Serbia and Hungary.

To date, 11 internationally-renowned centers have begun recruiting patients in those countries. First patients were treated in June 2013. 

The CHART-1 trial represents the world’s first Phase III trial for a pre-programmed cellular therapy targeting heart failure.

Professor Francesco Aviles, the Principal Investigator in Spain commented: “This approval allows Spanish medical institutions to start enrolling patients in the CHART-1 trial and join the group of other distinguished investigators that are already active in the trial. Six clinical centers are ready to start. We are proud to participate in this Phase III trial evaluating the benefit of C-Cure cardiopoietic cells for the treatment of severe heart failure. The Phase II data published in JACC earlier this year provide a strong scientific rationale for this technology and the potential it has to change the standard of care for our patients.”

Dr Christian Homsy, CEO of Cardio3 BioSciences, said: “The authorization by the Spanish authorities is another important step in our development plan. We believe our unique therapy offers the potential to revolutionize treatment for heart failure, a common and severe illness.”

The Phase III trial is a prospective, multi-centre, randomized, sham-controlled, patient-and evaluator-blinded study comparing treatment with C3BS-CQR-1 to a sham treatment. The trial will recruit a minimum of 240 patients with chronic advanced symptomatic heart failure. The primary endpoint of the trial is a composite endpoint including mortality, morbidity, quality of life, Six Minute Walk Test and left ventricular structure and function at 9 months post-procedure. 

Studies in additional countries will commence once national regulatory approvals have been received.

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Cardiology, Clinical

Footer

  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.
Cookie Policy | Privacy Policy | Terms of Use

Our website uses cookies including analytics cookies to help improve it by collecting statistics on how visitors use our website. By clicking on "I accept", you allow us to place these analytics cookies. We also use cookies that are necessary for the good functioning of our website. You can find out more information about the cookies we use by visiting our Cookie Policy. I acceptI refuseCookie Policy